Flumethasone

규격

2135-17-3CAS 번호

218-370-9EC 번호

(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-oneIUPAC 명칭

C22H28F2O5화학식

410.5 g/mol분자량

flumethasone; 2135-17-3; Flumetasone; Flucort; Flumetasona; Flumetasonum; DTXSID2045365; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione; U-10974; LR3CD8SX89; NSC-54702; U-10,974; DTXCID0025365; CHEBI:34764; NSC54702; Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,17,21-trihydroxy-16-methyl-, (6alpha,11beta,16alpha)-; Fluorodexamethasone; Bimasone; Flucort Tablets; Flucort Solution; Anaprime Suspension; flumethasoni pivalas; RefChem:55206; D07AB03; D07XB01; 218-370-9; Flucorticin; Flumethason; Anaprime; Methagon; Fluvet; Aniprime; Cortexilar; RS 2177; Flumetasone [INN]; RS-2177; Flumethasone [USAN]; C22H28F2O5; (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one; MLS000028618; Flumetasone (INN); Flumethasone (USAN); SMR000058690; MFCD00056464; Flumethasonum; 6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione (Flumetasone); Flucort (Veterinary); 6.alpha.-Fluorodexamethasone; 6alpha-Fluorodexamethasone; NSC 54702; Flumetasonum [INN-Latin]; 6-alpha-Fluorodexamethasone; Flumetasona [INN-Spanish]; NCGC00016604-01; 6alpha,9alpha-Difluoro-16alpha-methylprednisolone; Prestwick_229; CAS-2135-17-3; EINECS 218-370-9; BRN 5645455; Flumethasone (Standard); Opera_ID_1501; Prestwick0_000734; Prestwick1_000734; Prestwick2_000734; Prestwick3_000734; FLUMETHASONE [MI]; UNII-LR3CD8SX89; 6alpha-Fluoro-dexamethasone; SCHEMBL4046; BSPBio_000688; FLUMETASONE [WHO-DD]; MLS001077306; SPBio_002627; BPBio1_000758; orb1309688; orb3139668; 6,9-Difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; CHEMBL1201392; HY-B1051R; FLUMETHASONE [GREEN BOOK]; MSK2231; GLXC-20122; HMS1570C10; HMS2097C10; HMS2234B11; HMS3714C10; Flumetasone Pivalate EP Impurity A; HY-B1051; Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,17,21-trihydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)-; Tox21_110518; EBC-26989; MSK2231-100A; s4088; AKOS005256462; AKOS015895435; MSK2231-1000A; Tox21_110518_1; AC-2069; CCG-220734; CS-4573; DB00663; FF23328; SMP1_000127; NCGC00021761-03; NCGC00021761-05; NCGC00021761-06; (1R,2R,3aS,3bS,5S,9aS,9bR,10S,11aS)-5,9b-difluoro-1,10-dihydroxy-1-(2-hydroxyacetyl)-2,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one; AS-12534; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,17,21-trihydroxy-16alpha-methyl-(VAN); SY074151; F0945; NS00001953; D04208; EC 218-370-9; Flumethasone Solution in Acetonitrile, 100ug/mL; EN300-19734521; Flumethasone Solution in Acetonitrile, 1000ug/mL; SR-01000003144; Q4383636; SR-01000003144-3; BRD-K61496577-001-03-8; BRD-K61496577-001-20-2; 6.alpha., 9.alpha.-Difluoro-16.alpha.-methylprednisolone; (6a,11b,16a)-6,9-Difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; (6S,9R,10S,11S,13S,16R,17R)-6,9-Difluoro-11,17-dihydroxy-17-(2-hydroxy-acetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one; 6.alpha., 9-Difluoro-11.beta.,17,21-trihydroxy-16.alpha.-methylpregna-1, 4-diene-3,20-dione; 6|A,9-difluoro-11|A,17,21-trihydroxy-16|A- methylpregna-1,4-diene-3,20-dione (flumetasone); Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,17, 21-trihydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)-; Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,17,21-trihydroxy-16.alpha.-methyl-동의어